Interventions for Tuberculosis Control and Elimination 2002

1125. Kwon HH, Tomioka H, Saito H. Distribution and characterization of β-lactamases
of mycobacteria and related organisms. Tubercle Lung Dis 1995; 76: 141-8.
1126. Parenti F. New experimental drugs for the treatment of tuberculosis. Rev Infect
Dis 1989; 11: 479-83.
1127. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C,
Kocagöz S, Rosenberg E, Hadley WK, Nikaido H. Can penicillins and other
beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents
Chemother 1995; 39: 2620-4.
1128. Acred P, Hunter PA, Mizen L, Rolinson GN. α-amino-p-hydroxybenzylpenicillin
(BRL 2333), a new broad-spectrum semisynthetic penicillin: in vivo evaluation.
Antimicrob Agents Chemother 1970; 10: 416-22.
1129. Long AAW, Nayler JHC, Smith H, Taylor T, Ward N. Derivatives of 6aminopenicillanic
acid. Part XI. α-amino-p-hydroxy-benzylpenicillin. J Chem
Soc (C) 1971; 10: 1920-2.
1130. Tamás F. Use of amikacin and amoxicillin-clavulanic acid against
Mycobacterium tuberculosis. (Correspondence). Chest 1993; 104: 328.
1131. Cynamon MH, Palmer GS. In vitro activity of amoxicillin in combination with
clavulanic acid against Mycobacterium tuberculosis.
Chemother 1983; 24: 429-31.
Antimicrob Agents
1132. Bergmann JS, Woods GL. In vitro activity of antimicrobial combinations against
clinical isolates of susceptible and resistant Mycobacterium tuberculosis.
J Tuberc Lung Dis 1998; 2: 621-6.
Int
1133. Abate G, Miörner H. Susceptibility of multidrug-resistant strains of
Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid
and ethambutol. J Antimicrob Chemother 1998; 42: 735-40.
1134. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M. Amoxicillin-clavulanic
acid for treating drug-resistant Mycobacterium tuberculosis.
1025-6.
Chest 1991; 99:
1135. Yew WW, Wong CF, Lee J, Wong PC, Chau CH. Do β-lactam-β-lactamase
inhibitor combinations have a place in the treatment of multidrug-resistant pulmonary
tuberculosis? (Correspondence). Tubercle Lung Dis 1995; 76: 90-1.
1136. Chambers HF, Kocagöz T, Sipit T, Turner J, Hopewell PC. Activity of amoxicillin/clavulanate
in patients with tuberculosis. Clin Infect Dis 1998; 26: 874-7.
1137. Schraufnagel DE. Tuberculosis treatment for the beginning of the next century.
Int J Tuberc Lung Dis 1999; 3: 651-62.
1138. Saxon A, Beall GN, Rohr AS, Adelman DC. Immediate hypersensitivity reactions
to beta-lactam antibiotics. Ann Intern Med 1987; 107: 204-15.
1139. Neu HC. New macrolide antibiotics: azithromycin and clarithromycin.
(Editorial). Ann Intern Med 1992; 116: 515-7.
1140. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinetics
1999; 37: 385-98.
245